Y
Yujun Biotechnology
A company promoting the digital transformation of the four functional sectors of R&D, production, logistics and operation
About Yujun Biotechnology
Eyougene, incubated in Fudan Chemical and based in Lingang, Shanghai, specializes in the customized research and development (R&D) and production of small molecule intermediates. With over 60% of its personnel dedicated to R&D, the company offers a comprehensive suite of services, including process development and optimization for innovative drugs, and one-stop production services ranging from 100 grams to tons. Eyougene operates in the pharmaceutical and new material sectors, serving clients both domestically and internationally. The company adheres to a Digital Ecological Operation model, promoting digital transformation across R&D, production, logistics, and operations. Eyougene's core technologies include enzyme catalysis, metal catalysis, and special catalysis, which enhance reaction efficiency and selectivity while reducing costs. The company also focuses on the development of furandicarboxylic acid (FDCA), a bio-based aromatic polyester monomer with potential applications in amides, polycarbonates, and plasticizers, aiming to replace traditional PET (polyethylene terephthalate). Eyougene's business model revolves around providing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, generating revenue through customized R&D projects and large-scale production contracts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2023 | $28M | $110M | Lingdu Capital · Hangzhou Huadian Investment | ↗ |
Growth signals
Latest recorded traffic for Yujun Biotechnology is 1.4K monthly website visits, up 382.8% over the last three months. Yujun Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yujun Biotechnology in its local ecosystem
The Yujun Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- LCLingdu Capital
- HIHangzhou Huadian Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yujun Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yujun Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







